LAVA Therapeutics (NASDAQ:LVTX) Short Interest Up 178.2% in December

LAVA Therapeutics (NASDAQ:LVTX) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 58,700 shares, an increase of 178.2% from the November 30th total of 21,100 shares. Based on an average daily volume of 89,100 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.4% of the company’s shares are sold short.

LAVA Therapeutics Stock Up 0.1 %

Shares of LVTX stock traded up $0.00 during mid-day trading on Friday, reaching $0.99. The company’s stock had a trading volume of 253,037 shares, compared to its average volume of 515,669. The company’s 50 day simple moving average is $1.56 and its 200-day simple moving average is $1.73. LAVA Therapeutics has a 12-month low of $0.88 and a 12-month high of $6.47. The firm has a market capitalization of $25.18 million, a PE ratio of -0.96 and a beta of 0.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of LAVA Therapeutics during the third quarter worth $32,000. Pathway Financial Advisors LLC lifted its holdings in LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after buying an additional 42,500 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in LAVA Therapeutics in the 2nd quarter valued at about $55,000.

Analysts Set New Price Targets

LVTX has been the subject of a number of recent analyst reports. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. HC Wainwright dropped their price objective on shares of LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Leerink Partnrs lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, JMP Securities reaffirmed a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.33.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.